Researchers conducted a network meta-analysis to compare different treatments for patients with advanced medullary thyroid cancer. The study looked at 1,076 patients who were treated with drugs including selpercatinib, cabozantinib, vandetanib, and anlotinib. These medications are used to manage the growth of the cancer.
The results showed that selpercatinib provided the most significant benefit for progression-free survival compared to both cabozantinib and vandetanib. It also ranked first in terms of objective response rate. While some drugs in this group, like anlotinib, showed higher toxicity levels, selpercatinib was noted for avoiding certain common side effects like hypertension and diarrhea.
It is important to note that the study included a diverse group of patients with different mutation statuses and treatment histories. Because of this mix, the results might not apply perfectly to every specific type of patient. Doctors should still consider each patient's unique situation before choosing a treatment plan.
